NOD2c.3019-3020insC AND c.2104C>T GENE VARIANTS AMONG PATIENTS FROM WESTERN UKRAINE WITH CROHN’S DISEASE AND COLORECTAL CANCER
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17305Keywords:
3020insC and R702W mutations of NOD2 gene, colorectal cancer., Crohn’s disease, disease onset, gender., surgical interventionsAbstract
Aim: To determine the frequency of NOD2 gene c.3019-3020insC (rs5743293) and c.2104C>T (rs2066844) allelic variants in the patients with Crohn’s disease (CD), colorectal cancer (CRC) and in the control groups and to study the association of these mutations with the onset time of the diseases, gender and surgical interventions. Materials and Methods: The diagnoses of CD and CRC were established based on standard clinical examination and laboratory tests. Molecular genetic study of a frameshift 3020insC mutations of NOD2 gene were performed in 54 patients with CD; missense R702W mutations of the NOD2 gene — in 41 CD patients and 38 healthy controls. In CRC group, 3020insC mutation was tested in 48 patients, R702W mutation — in 40 patients and 40 healthy controls. PCR-RFLP technique was used to identify the mutations. Results: The frequency of the minor allele (M) of 3020insC mutation of NOD2 gene in the patients with CD was significantly higher than in the control group (р = 0.01). The age at CD onset in females carrying 3020insC mutation was significantly lower (22.5 ± 1.6 years) when compared with females without the mutation (32.7 ± 2.5 years) (p = 0.002). There was no significant difference in the allele frequencies and genotype distributions of R702W mutation in the patients with CD in comparison with the controls. The mean age at CD onset in the patients carrying R702W mutation was significantly lower (28.4 ± 1.4 years) compared with the patients without the mutation (39.4 ± 2.8 years) (p < 0.01). Surgical interventions for CD was required in 40.0% of 3020insC mutation carriers. Among patients with CRC, only 4.2% carried 3020insC mutation and 20.0% R702W mutation. Our study suggests that R702W and 3020insC mutations are not associated with the risk of CRC in Ukrainian patients. There was no statistically significant difference in mean age at CRC onset in patients with/without R702W mutation. Only one patient with CRC had two mutations. Conclusion: The earlier age at CD onset was associated with 3020insC mutation, but only in female patients. The association between R702W mutation and the earlier age of CD onset was found. Patients with 3020insC mutation showed a trend to a higher frequency of surgical interventions for CD.
References
Lau TP, Roslani AC, Lian LH, et al. NOD2/CARD15 variants in Malaysian patients with sporadic colorectal cancer. Genet Mol Res 2014; 13: 7079–85. https://doi.org/10.4238/2014.March.19.3
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. Cancer J 2014; 64: 104–17. https://doi.org/10.3322/caac.21220
Bulletin of the National Cancer Registry of Ukraine 21, Cancer in Ukraine, 2018–2019. http://www.ncru.inf.ua.
Branquinho D, Freire P, Sofia C. NOD2 mutations and colorectal cancer — Where do we stand? World J Gastrointest Surg 2016; 8: 284–93. https://doi.org/10.4240/wjgs.v8.i4.284
Cho M, Carter J, Harari S, Pei Z. The inter relationships of the gut microbiome and inflammation in colorectal carcinogenesis. Clin Lab Med 2014; 34: 699–710. https://doi.org/10.1016/j.cll.2014.08.002
Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013; 11: 1601–8. https://doi.org/10.1016/j.cgh.2013.06.023
Boland CR. Chronic inflammation, colorectal cancer and gene polymorphisms. Dig Dis 2010; 28: 590–5. https://doi.org/10.1159/000320053
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54. e42; quiz e30. https://doi.org/10.1053/j.gastro.2011.10.001
Dorofeev AE. Crohn’s disease: classification, diagnosis and treatment. News Med Pharm Gastroenterol 2010; (313) (in Russian). Retrieved from http://www.mif-ua.com/archive/article/16363
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterol 2011; 140: 1785–94. https://doi.org/10.1053/j.gastro.2011.01.055
Sica GS, Biancone L. Surgery for inflammatory bowel disease in the era of laparoscopy. World J Gastroenterol 2013; 19: 2445–8. https://doi.org/10.3748/wjg.v19.i16.2445
Sipos F, Molnár B, Zágoni T, et al. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Colon Rectum 2005; 48: 775–86. https://doi.org/10.1007/s10350-004-0831-5
Deng W, Xie J. NOD2 signaling and role in pathogenic mycobacterium recognition, infection and immunity. Cell Physiol Biochem 2012; 30: 953–63. https://doi.org/10.1159/000341472
Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869–72. https://doi.org/10.1074/jbc.C200651200
Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411: 603–6. https://doi.org/10.1038/35079114
Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599–603. https://doi.org/10.1038/35079107
Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001; 357: 1925–8. https://doi.org/10.1016/S0140-6736(00)05063-7
Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71: 74–83. https://doi.org/10.1086/341124
Lesage S, Zouali H, Cézard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845–57. https://doi.org/10.1086/339432
Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn’s disease. Gastroenterology 2002; 122: 854–66. https://doi.org/10.1053/gast.2002.32413
Bhullar M, Macrae F, Brown G, et al. Prediction of Crohn’s disease aggression through NOD2/CARD15 gene sequencing in an Australian cohort. World J Gastroenterol 2014; 20: 5008–16. https://doi.org/10.3748/wjg.v20.i17.5008
Brant SR, Panhuysen CI, Bailey-Wilson JE, et al. Linkage heterogeneity for the IBD1 locus in Crohn’s disease pedigrees by disease onset and severity. Gastroenterol 2000; 119: 1483–90. https://doi.org/10.1053/gast.2000.20245
Barreiro M, Núñez C, Domínguez-Muñoz JE, et al. Association of NOD2/CARD15 mutations with previous surgical procedures in Crohn’s disease. Rev Esp Enferm Dig 2005; 97: 547–53. https://doi.org/10.4321/s1130-01082005000800002
Seiderer J, Schnitzler F, Brand S, et al. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn’s disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol 2006; 41: 1421–32. https://doi.org/10.1080/00365520600703900
Büning C, Genschel J, Bühner S, et al. Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004; 19: 1073–8. https://doi.org/10.1111/j.1365-2036.2004.01967.x
Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005; 242: 693–700. https://doi.org/10.1097/01.sla.0000186173.14696.ea
Maconi G, Colombo E, Sampietro GM, et al. CARD15 gene variants and risk of reoperation in Crohn’s disease patients. Am J Gastroenterol 2009; 104: 2483–91. https://doi.org/10.1038/ajg.2009.413
Lacher M, Helmbrecht J, Schroepf S, et al. NOD2 mutations predict the risk for surgery in pediatric-onset Crohn’s disease. J Pediatr Surg 2010; 45: 1591–7. https://doi.org/10.1016/j.jpedsurg.2009.10.046
Tuupanen S, Alhopuro P, Mecklin J.-P, Aaltonen LA. No evidence for association ofNOD2 R702W and G908R with colorectal cancer. Int J Cancer 2007; 121: 76–9. https://doi.org/10.1002/ijc.22651
Lubiński J, SuchyJ, Kurzawski G, et al. Determining a predisposition to cancer. United States Patent (10) Patent No.: US 7.407,755 B2; (45) Date of Patent: Aug. 5, 2008. http://patentimages.storage.google.apis.com.
Jaskula E, Lange A, Kyrcz-Krzemien S, et al. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 409–14. https://doi.org/10.1016/j.bbmt.2013.12.558
Lubiński J, Huzarski T, Kurzawski G, et al. The 3020insC allele of NOD2 predisposes to cancers of multiple organs. Hered Cancer Clin Prac 2005; 3: 59. https://doi.org/10.1186/1897-4287-3-2-59
Arnott ID, Nimmo ER, Drummond HE, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn’s disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 2004; 5: 417–25. https://doi.org/10.1038/sj.gene.6364111
Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845–57. https://doi.org/10.1086/339432
Renda MC, Orlando A, Civitavecchia G, et al. The role of CARD15 mutations and smoking in the course of Crohn’s disease in a Mediterranean area. Am J Gastroenterol 2008; 103: 649–55. https://doi.org/10.3748/wjg.14.4454
Croucher PJ, Mascheretti S, Hampe J, et al. Haplotype structure and association to Crohn’s disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003; 11: 6–16. doi.org/10.1038/sj.ejhg.5200897
Yamazaki K, Takazoe M, Tanaka T, et al. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn’s disease. J Hum Genet 2002; 47: 469–72. https://doi.org/10.1007/s100380200067
Leong RW, Armuzzi A, Ahmad T, et al. NOD2/CARD15 gene polymorphisms and Crohn’s disease in the Chinese population. Aliment Pharmacol Ther 2003; 17: 1465–70. https://doi.org/10.1046/j.1365-2036.2003.01607.x
Wang ZW, Ji F, Teng WJ, et al. Risk factors and gene polymorphisms of inflammatory bowel disease in population of Zhejiang, China.World J Gastroenterol 2011; 17: 118–22. https://doi.org/10.3748/wjg.v17.i1.118
Jadallah KA, Daoud AK, Nasra ONA, et al. Frequency of three common mutations of CARD15/NOD2 gene in Jordanian patients with Crohn’s disease. Br J Med & Med Res 2015; 7: 93–105. https://doi.org/10.9734/BJMMR/2015/15953
Yamazaki K, Umeno J, Takahashi A, et al. A genome-wide association study identifies 2 susceptibility loci for Crohn’s disease in a Japanese population. Gastroenterol 2013; 144: 781–8. https://doi.org/10.1053/j.gastro.2012.12.021
Kurzawski G, Suchy J, Kładny J, et al.T heNOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res 2004; 64: 1604–6. https://doi.org/10.1158/0008-5472.can-03-3791
Lozynska LY. Crohn’s disease-associated neoplasms: frequency, spectrum, gender and age features of occurrence, the surgical interventions types. Khirurgiia Ukr 2016; 3: 78–82 (in Ukrainian).
Burada F, Mirea CS, Cucu MG, et al. The association between NOD2 R702W polymorphism and susceptibility to colorectal cancer in Romanian patients. Curr Health Sci J 2018; 44: 135–9. https://doi.org/10.12865/CHSJ.44.02.07
Zaridze DG. Molecular epidemiology of cancer. Biochemistry (Mosc) 2008; 73: 532–42. https://doi.org/10.1134/s0006297908050064
Omrane I, Mezlini A, Baroudi O, et al. 3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer. Med Oncol 2014; 31: 954. https://doi.org/10.1007/s12032-014-0954-z
Freire P, Portela F, Donato M, et al. CARD15 mutations and colorectal cancer in a South European country. Int J Colorectal Dis 2010; 25: 1211–9. https://doi.org/10.1007/s00384-010-1028-0
Tian Y, Li Y, Hu Z, et al. Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis. Int J Colorectal Dis 2010; 25: 161–8. https://doi.org/10.1007/s00384-009-0809-9
HeJC, Xu Q, Xing C, YuanY..NOD2 polymorphisms associated with cancer risk: a meta-analysis. PLoSOne 2014; 9: e89340. https://doi.org/10.1371/journal.pone.0089340
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
